Overview
Smart money at a glance
Filings to Oct 5, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 1 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $1.88
- 52-wk high
- $10.38
- High
- $1.88
- 52-wk low
- $1.72
- Low
- $1.72
- Prev close
- $1.89
- Mkt cap
- $168.7M
- Volume
- 1.99M
- Fwd P/E
- 3.9x
- Beta
- 1.14
- P/B
- 1.9x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -12.8%
What do analysts expect?
No analyst estimates.
Questions about AVXL filings
Are insiders buying or selling Anavex Life Sciences Corp (AVXL) stock?
Neither. Anavex Life Sciences Corp (AVXL) insiders filed no open-market purchases or sales in the 90 days to Oct 5, 2026, according to SEC Form 4 filings.
Which members of Congress have traded AVXL recently?
None. No member of Congress disclosed a AVXL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this AVXL smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Sells/Trims (1)
- SS
State Street
$8.9M
trimmed
How top traders are positioned
No tracked top-trader positions in AVXL right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $0.16 a share above what analysts expected.
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.08 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $0.08 / -$0.08Alpha Vantage | +$0.16 beat | Unavailable | Unavailable |
| Mar 31, 2026 | Jun 23, 2026 | -$0.13 / -$0.07Alpha Vantage | -$0.06 miss | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 9, 2026 | -$0.06 / -$0.11Alpha Vantage | +45.45% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 25, 2025 | -$0.11 / -$0.14Alpha Vantage | +22.86% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 12, 2025 | -$0.16 / -$0.14Alpha Vantage | -14.29% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 13, 2025 | Unavailable | - | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 12, 2025 | -$0.14 / -$0.17Alpha Vantage | +17.65% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Dec 23, 2024 | -$0.14 / -$0.17Alpha Vantage | +17.65% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 24, 2026, in 50 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Forward P/E
- 3.85
- Market cap
- $169M
Valuation
- P/B1.93
Quality
- Operating margin0.0%
- ROE-12.8%
- ROA-9.7%
Growth
- Beta1.14
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace